<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>ECC5004: what changed | Grey Peptides</title>
    <link>https://greypeptides.com/changes/#e-ecc5004</link>
    <atom:link href="https://greypeptides.com/changes/ecc5004.xml" rel="self" type="application/rss+xml" />
    <description>News, regulatory alerts, corrections and new guides about ECC5004 on Grey Peptides, newest first.</description>
    <language>en-us</language>
    <lastBuildDate>Fri, 16 Oct 2026 12:00:00 +0000</lastBuildDate>
    <ttl>1440</ttl>
    <item>
      <title>News: Elecoglipron in Phase 2: What the VISTA and SOLSTICE Trials Show</title>
      <link>https://greypeptides.com/news/elecoglipron-phase-2-vista-solstice/</link>
      <guid isPermaLink="false">greypeptides-changes-ecc5004-news-elecoglipron-phase-2-vista-solstice</guid>
      <pubDate>Fri, 16 Oct 2026 12:00:00 +0000</pubDate>
      <category>News</category>
      <description>Elecoglipron in Phase 2: What the VISTA and SOLSTICE Trials Show</description>
    </item>
  </channel>
</rss>
